U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry EPIMERIC
Molecular Formula C25H34O6
Molecular Weight 430.5339
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUDESONIDE

SMILES

[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(CCC)O2)C(=O)CO

InChI

InChIKey=VOVIALXJUBGFJZ-KWVAZRHASA-N
InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1

HIDE SMILES / InChI
Molecular Formula C25H34O6
Molecular Weight 430.5339
Charge 0
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 8 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:43:03 UTC 2023
Edited
by admin
on Sat Dec 16 15:43:03 UTC 2023
Record UNII
Q3OKS62Q6X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BUDESONIDE
EP   INN   JAN   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
BREZTRI COMPONENT BUDESONIDE
Brand Name English
ORTIKOS
Brand Name English
AIRSUPRA COMPONENT BUDESONIDE
Brand Name English
Budesonide [WHO-DD]
Common Name English
BUDESONIDE [USAN]
Common Name English
UCERIS COMPONENT BUDESONIDE
Brand Name English
BUDESONIDE COMPONENT OF UCERIS
Brand Name English
ENTOCORT
Brand Name English
S-1320
Code English
BUDESONIDE [VANDF]
Common Name English
RHINOCORT
Brand Name English
BUDESONIDE [EP MONOGRAPH]
Common Name English
PULMICORT
Brand Name English
BUDESONIDE [MI]
Common Name English
R01AD05
Code English
budesonide [INN]
Common Name English
BUDESONIDE COMPONENT OF SYMBICORT
Common Name English
BUDESONIDE COMPONENT OF BREZTRI
Brand Name English
SYMBICORT COMPONENT BUDESONIDE
Common Name English
UCERIS
Brand Name English
MAP-0010
Code English
BUDESONIDE [ORANGE BOOK]
Common Name English
BUDESONIDE COMPONENT OF AIRSUPRA
Brand Name English
NSC-757788
Code English
BUDESONIDE [USP MONOGRAPH]
Common Name English
MAP0010
Code English
BUDESONIDE [USP-RS]
Common Name English
BUDESONIDE [JAN]
Common Name English
ENTOCORT EC
Brand Name English
(RS)-11β,16α,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde
Common Name English
Classification Tree Code System Code
WHO-VATC QR03BA02
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
WHO-ATC R03BA02
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
FDA ORPHAN DRUG 673818
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
EMA ASSESSMENT REPORTS VYLAER SPIROMAX (AUTHORIZED: ASTHMA, PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
FDA ORPHAN DRUG 634418
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
WHO-ATC R03AK07
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
FDA ORPHAN DRUG 394613
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
FDA ORPHAN DRUG 305710
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
WHO-ATC R03AK12
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
NDF-RT N0000175576
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
EMA ASSESSMENT REPORTS DUORESP SPIROMAX (AUTHORIZED: ASTHMA, PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 25.1
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
WHO-ATC D07AC09
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
FDA ORPHAN DRUG 227406
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
WHO-ATC A07EA06
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
LIVERTOX NBK548351
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
FDA ORPHAN DRUG 670118
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
WHO-VATC QR01AD05
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
EMA ASSESSMENT REPORTS BIRESP ( AUTHORIZED: ASTHMA, PLUMONARY DISEASE, CRONIC OBSTRUCTIVE)
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
EU-Orphan Drug EU/3/13/1181
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
EMA ASSESSMENT REPORTS LABAZENIT (REFUSED: ASTHMA)
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
NDF-RT N0000175450
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
NCI_THESAURUS C521
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
WHO-ATC R01AD05
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 28
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
WHO-VATC QR03AK07
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
WHO-VATC QA07EA06
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
EMA ASSESSMENT REPORTS BUDESONIDA (AUTHORIZED: ASTHMA, PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
WHO-VATC QD07AC09
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
Code System Code Type Description
EVMPD
SUB05955MIG
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
INN
4145
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
DAILYMED
Q3OKS62Q6X
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
NCI_THESAURUS
C1027
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
LACTMED
Budesonide
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
PUBCHEM
5281004
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
ECHA (EC/EINECS)
257-139-7
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
DRUG BANK
DB01222
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
FDA UNII
Q3OKS62Q6X
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
RXCUI
19831
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY RxNorm
MESH
D019819
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
CHEBI
3207
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
IUPHAR
7434
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
RS_ITEM_NUM
1078201
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
DRUG CENTRAL
419
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
CAS
51333-22-3
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
MERCK INDEX
m2746
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY Merck Index
NSC
757788
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
EPA CompTox
DTXSID8020202
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
WIKIPEDIA
BUDESONIDE
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
ChEMBL
CHEMBL1370
Created by admin on Sat Dec 16 15:43:08 UTC 2023 , Edited by admin on Sat Dec 16 15:43:08 UTC 2023
PRIMARY
Related Record Type Details
Structure of BUDESONIDE
EXCRETED UNCHANGED
No unchanged budesonide is detected in urine.
URINE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
Plasma protein binding is estimated to be 85 to 90% in the concentration range 1 to 230 nmol/L, independent of gender.
BINDING
Related Record Type Details
Structure of 6.BETA.-HYDROXYBUDESONIDE
METABOLITE -> PARENT
In vitro mediator: CYP3A4
Structure of 11-KETO-4,5-DIHYDRO-16.ALPHA.-HYDROXYPREDNISOLONE
METABOLITE -> PARENT
Catalyzed by two enzymes, the 4-ene-5.BETA.-reductase and the 4-ene-5.ALPHA.-reductase
MINOR
URINE
Structure of 16.ALPHA.-HYDROXYPREDNISOLONE
METABOLITE -> PARENT
In vitro mediator: CYP3A4
Structure of 16.ALPHA.,20-DIHYDROXYPREDNISOLONE, (20S)-
METABOLITE -> PARENT
MINOR
URINE
Structure of 11-KETO BUDESONIDE
METABOLITE -> PARENT
MINOR
URINE
Structure of 11-KETO-16.ALPHA.-HYDROXYPREDNISOLONE
METABOLITE -> PARENT
MINOR
URINE
Structure of 6,7-DEHYDRO-23-HYDROXYBUDESONIDE, (23R)-
METABOLITE -> PARENT
MINOR
URINE
Structure of 6,7-DEHYDRO-23-HYDROXYBUDESONIDE, (23S)-
METABOLITE -> PARENT
MINOR
URINE
Structure of 6.BETA.-HYDROXYBUDESONIDE
METABOLITE -> PARENT
MINOR
URINE
Structure of 16.ALPHA.,20-DIHYDROXYPREDNISOLONE, (20R)-
METABOLITE -> PARENT
MINOR
URINE
Structure of TPI-1020
PRODRUG -> METABOLITE ACTIVE
Structure of 23-HYDROXYBUDESONIDE, (S)-
METABOLITE -> PARENT
MINOR
URINE
Structure of 16.ALPHA.-HYDROXYPREDNISOLONE
METABOLITE -> PARENT
MAJOR
URINE
Structure of 23-HYDROXYBUDESONIDE, (R)-
METABOLITE -> PARENT
MINOR
URINE
Structure of .DELTA.6-BUDESONIDE
METABOLITE -> PARENT
MINOR
URINE
Structure of 20-HYDROXYBUDESONIDE, (S)-
METABOLITE -> PARENT
MINOR
URINE
Structure of 4,5-DIHYDRO-16.ALPHA.-HYDROXYPREDNISOLONE
METABOLITE -> PARENT
Catalyzed by two enzymes, the 4-ene-5.BETA.-reductase and the 4-ene-5.ALPHA.-reductase
MINOR
URINE
Structure of 6.ALPHA.-HYDROXYBUDESONIDE
METABOLITE -> PARENT
MINOR
URINE
Structure of 11-KETO-4,5-DIHYDRO-3,16.ALPHA.-DIHYDROXYPREDNISOLONE
METABOLITE -> PARENT
Catalyzed by two enzymes, the 4-ene-5.BETA.-reductase and the 4-ene-5.ALPHA.-reductase. The second stage utilizes the enzymes 3.ALPHA.- and, to a much lesser extent, 3.BETA.-hydroxysteroid dehydrogenases
MINOR
URINE
Related Record Type Details
Structure of 1,2-DIHYDROBUDESONIDE
IMPURITY -> PARENT
Limit includes both epimers
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 16.ALPHA.-(BUTYRYLOXY)PREDNISOLONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 9.ALPHA.-BROMOBUDESONIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 11-KETO BUDESONIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 9,11-ANHYDROBUDESONIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of D-HOMOBUDESONIDE
IMPURITY -> PARENT
This impurity is to be reported under total unspecified impurities. Do not report it under total specified impurities.
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 16.ALPHA.,17-(ETHYLIDENEBIS(OXY))-11.BETA.,21-DIHYDROXYPREGNA-1,4-DIENE-3,20-DIONE
IMPURITY -> PARENT
Limit includes both epimers
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DESONIDE
IMPURITY -> PARENT
This impurity is to be reported under total unspecified impurities. Do not report it under total specified impurities.
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of BUDESONIDE 21-ACETATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BUDESONIDE 21-BUTYRATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 14,15-DEHYDROBUDESONIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of ANDROSTA-1,4-DIENE-3,17-DIONE, 11-HYDROXY-16-(1-OXOBUTOXY)-, (11.BETA.,16.ALPHA.)-
IMPURITY -> PARENT
Implied to be a potential or real impurity
Structure of 21-DEHYDROBUDESONIDE
IMPURITY -> PARENT
Limit includes both epimers
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 16.ALPHA.-HYDROXYPREDNISOLONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966